Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group.

Thea Chandler, Indrani Karpha, Nurunnahar Akter, Temitope Erinfolami, Hanhua Liu, Brogan Johnston, Yeong Lim, Nagesh Kalakonda, Gillian Brearton, Sally Moore, Hira Mian, Frances Seymour, Christopher Parrish, Charlotte Pawlyn, Catrin Tudur Smith, Andrew Pettitt, Gordon Cook

Blood (2025) 146 (Supplement 1): 2792.

https://doi.org/10.1182/blood-2025-2792

Published: 2025

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Blood (2025) 146 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2025-2204

Published: 2025

Journal Articles

Patterns of palliative care utilization across health sectors in patients with aggressive non-Hodgkin lymphoma.

Joanne Britto, Ana Gayowsky, Hira Mian, Amaris Balitsky, Graeme Fraser, Gwynivere Davies, Tom Kouroukis, Ronan Foley, Hsien Seow

Blood (2025) 146 (Supplement 1): 6268.

https://doi.org/10.1182/blood-2025-6268

Published: 2025

Journal Articles

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Blood (2025) 146 (Supplement 1): 133.

https://doi.org/10.1182/blood-2025-133

Published: 2025

Journal Articles

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4588.

https://doi.org/10.1182/blood-2025-4588

Published: 2025

Journal Articles

Real-world outcomes of transplant-ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens

Salomon Manier, Lauren E. Cain, Quan Chen, Sunny He, Kaustav Chatterjee, Hira Mian

Blood (2025) 146 (Supplement 1): 6341.

https://doi.org/10.1182/blood-2025-6341

Published: 2025

Journal Articles

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Simon Harrison, Caroline Hasselbalch Riley, Hira Mian, Andrew Spencer, Noa Lavi, Laura Paris, Jana Mihalyova, Rakesh Popat, Monika Szarejko, Sebastian Grosicki, Kihyun Kim, Irwindeep Sandhu, Sammy Chebon, Tulika Tyagi, Paresh Sewpaul, Leanne Richardson, Kerstin Trunzer, Ameet Mishra, Suzanne Trudel

Blood (2025) 146 (Supplement 1): 252.

https://doi.org/10.1182/blood-2025-252

Published: 2025

Journal Articles

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (9): 1051–1064.

https://doi.org/10.1182/blood.2024027873

Published: 2025

Includes: Supplemental data

Journal Articles

Hypercalcemia in MGUS: keep the differential diagnosis broad

Hira Mian, Alissa Visram

Blood (2025) 145 (9): 904–905.

https://doi.org/10.1182/blood.2024027928

Published: 2025

Journal Articles

Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Blood (2024) 144 (Supplement 1): 4733.

https://doi.org/10.1182/blood-2024-200071

Published: 2024

Journal Articles

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Hira Mian, Carlyn Rose Tan, Sireesha Asoori, Rakesh Popat, Nadine Abdallah, Saurabh Chhabra, Ricardo D. Parrondo, Gregory R Pond, Thomas Martin, Brian G.M. Durie, Yi Lin

Blood (2024) 144 (Supplement 1): 704.

https://doi.org/10.1182/blood-2024-200877

Published: 2024

Journal Articles

Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Imran Haider, Darryl P. Leong, Martha L Louzada, Arleigh McCurdy, Gregory R Pond, Ruthanne Cameron, Mohammed Aljama, Alissa Visram, Tanya M. Wildes, Hira Mian

Blood (2024) 144 (Supplement 1): 703.

https://doi.org/10.1182/blood-2024-205524

Published: 2024

Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2024-198119

Published: 2024

Journal Articles

Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study

Andrew J. Cowan, Luuk Gras, Hiroyuki Takamatsu, Linda Koster, Laurien Baaij, III, Nada Hamad, Anita D'Souza, Noel Estrada-Merly, Parameswaran N. Hari, Wael Saber, Minako Iida, Shinichiro Okamoto, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Bor-Sheng Ko, Christopher Liam, KIM Wah HO, A Sim Goh, S Keat Tan, Alaa M. Elhaddad, Ali Bazarbachi, Brig Qamar Un N Chaudhry, Rozan Alfar, Mohamed Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Sebastian Galeano, Francisca Bass, Hira Mian, Arleigh McCurdy, Feng-Rong Wang, Meng Lv, Daniel Neumann, Mickey Boon Chai Koh, John Snowden, Stefan Schonland, Donal P McLornan, Patrick John Hayden, Rafael De La Camara, Raffaella Greco, Fabio Ciceri, Mette D. Hazenberg, Anna Sureda Balari, Damiano Rondelli, Hildegard T. Greinix, Mahmoud Aljurf, Yoshiko Atsuta, Dietger W. Niederwieser, Laurent Garderet

Blood (2024) 144 (Supplement 1): 2379.

https://doi.org/10.1182/blood-2024-205709

Published: 2024

Journal Articles

Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study

Amaris K Balitsky, Gregory R Pond, Hira Mian, Gwynivere A Davies, Ronan Foley, Graeme Andrew McCrae Fraser, Jonathan Sussman, C. Tom Kouroukis

Blood (2024) 144 (Supplement 1): 3753.

https://doi.org/10.1182/blood-2024-200461

Published: 2024

Journal Articles

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Murali Janakiram, Carlyn Rose Tan, Rakesh Popat, Joaquín Martínez Lopez, Efstathios Kastritis, Chris Lau, Wee-Joo Chng, Prashant Kapoor, Hira Mian, Susan Bal, Ajay K. Nooka, Andre De Menezes Silva Corraes, Magdalena Corona, Arnab Chowdhury, Yi Lin, Thomas G Martin, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2024-211167

Published: 2024

Journal Articles

Race and Ethnicity As a Category Poses Challenges in Global Registries: Experience from the Waustim Project of the Worldwide Network for Blood and Marrow Transplantation, WBMT

Nada Hamad, Hiroyuki Takamatsu, Luuk Gras, Linda Koster, Laurien Baaij, Anita D'Souza, Noel Estrada-Merly, Parameswaran N. Hari, Andrew J. Cowan, Wael Saber, Minako Iida, Shinichiro Okamoto, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Bor-Sheng Ko, KIM Wah HO, Christopher Liam, A Sim Goh, Sui Tan, Hira Mian, Ali Bazarbachi, Brig Qamar Un N Chaudhry, Rozan Alfar, Mohamed Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Sebastian Galeano, Francisca Bass, Arleigh McCurdy, Alaa Elhaddad, Feng Rong Wang, Meng Lv, Mickey Boon Chai Koh, John Snowden, Stefan Schonland, Donal P McLornan, Mette Heisenberg, Patrick J Hayden, Daniel Neumann, Rafael De La Camara, Raffaella Greco, Fabio Ciceri, Anna Sureda Balari, Anna Sureda Balari, Damiano Rondelli, Hildegard T. Greinix, Mahmoud Aljurf, Yoshiko Atsuta, Dietger W. Niederwieser, Laurent Garderet

Blood (2024) 144 (Supplement 1): 7848.

https://doi.org/10.1182/blood-2024-209898

Published: 2024

Journal Articles

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Jehad Almasri, Bashar Hasan, Zin Tarakji, Faris W. Naffa', Lynn Warner, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 6986.

https://doi.org/10.1182/blood-2024-206645

Published: 2024

Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau

Blood (2024) 144 (Supplement 1): 4757.1.

https://doi.org/10.1182/blood-2024-199752

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group.

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Patterns of palliative care utilization across health sectors in patients with aggressive non-Hodgkin lymphoma.

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Real-world outcomes of transplant-ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Hypercalcemia in MGUS: keep the differential diagnosis broad

Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis

Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Race and Ethnicity As a Category Poses Challenges in Global Registries: Experience from the Waustim Project of the Worldwide Network for Blood and Marrow Transplantation, WBMT

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only